MMMasaaki Miyamoto

Masaaki Miyamoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masaaki Miyamoto has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Gen Takagi

    Division of Cardiology and Regenerative Medicine, Department of Internal Medicine, Nippon Medical School

    6 shared publications
  • Hiroshi Mizuno

    Department of Plastic and Reconstructive Surgery, Nippon Medical School, Tokyo, Japan

    3 shared publications
  • Hitoshi Takano

    Division of Cardiology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan

    3 shared publications
  • Masahiro Yasutake

    Division of Cardiology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan

    3 shared publications
  • Shinichiro Kumita

    Department of Radiology, Nippon Medical School, Tokyo, Japan

    3 shared publications
  • Sonoko Kirinoki-Ichikawa

    Division of Cardiology and Regenerative Medicine, Department of Internal Medicine, Nippon Medical School

    3 shared publications

Latest Publications

  • Open Access

    Low-energy Extracorporeal Shock Wave Therapy Improves Microcirculation Blood Flow of Ischemic Limbs in Patients with Peripheral Arterial Disease: Pilot Study

    by Shuhei Tara, Masaaki Miyamoto, Gen Takagi, Sonoko Kirinoki-Ichikawa, Akito Tezuka, Tomohito Hada, Ikuyo Takagi

    Background: Because direct application of low-energy shock waves induces angiogenesis, we investigated the safety and efficacy of this new therapy to develop a noninvasive method of repeatable therapeutic angiogenesis for treating peripheral arterial disease (PAD). Subjects and Methods: The subjects were 10 patients who had symptomatic PAD and limited ischemia in a below-the-knee artery. Low-energy shock waves were directly applied to the calf muscles 6 times every other day. Intracorporeal changes were evaluated with ultrasonography to determine adverse effects of therapy. To assess blood flow of the microcirculation, transcutaneous oxygen tension (TcPO2), skin perfusion pressure (SPP), and 99mtechnetium-tetrofosmin (99mTc-TF) scintigraphy were performed before and after therapy. The TcPO2 was measured while subjects inhaled pure oxygen (maximum TcPO2). The 99mTc-TF perfusion index was determined as a ratio of uptake in muscle to that in the brain (control) for quantitative analysis. Results: No adverse effects were noted in any patient. Maximum TcPO2 values increased significantly on the calf (57.3±28.4 to 71.0±14.5 mm Hg, p=0.044) and the dorsum of the foot (52.2±21.8 to 76.1±17.9 mm Hg, p=0.012). The SPP tended to increase after therapy on the dorsum and plantar surfaces of the foot, but the differences were not significant. The 99mTc-TF perfusion index in the foot significantly increased (0.48±0.09 to 0.61±0.12, p=0.0013), but that in the leg did not change. Conclusion: We have demonstrated that low-energy shock wave therapy is safe and can restore blood flow in the microcirculation in patients with symptomatic PAD.


  • Open Access

    The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes

    by Yoshiaki Kubota, Masaaki Miyamoto, Gen Takagi, Takeshi Ikeda, Sonoko Kirinoki-Ichikawa, Kotoko Tanaka, Kyoichi Mizuno

    Kubota Y, et al. J Korean Med Sci. 2012 Nov;27(11):1364-1370. http://dx.doi.org/10.3346/jkms.2012.27.11.1364


  • Open Access

    Therapeutic Vascular Angiogenesis for Vasculitis Related Peripheral Artery Disease

    by Gen Takagi, Masaaki Miyamoto, Yasuhiko Tabata, Kyoichi Mizuno

  • Open Access

    Prediction of Limb Salvage after Therapeutic Angiogenesis by Autologous Bone Marrow Cell Implantation in Patients with Critical Limb Ischemia

    by Shuhei Tara, Masaaki Miyamoto, Gen Takagi, Yoshimitsu Fukushima, Sonoko Kirinoki-Ichikawa, Hitoshi Takano, Ikuyo Takagi, Hiroshi Mizuno, Masahiro Yasutake, Shinichiro Kumita, et al.

    Purpose: Despite advances in therapeutic angiogenesis by bone marrow cell implantation (BMCI), limb amputation remains a major unfavorable outcome in patients with critical limb ischemia (CLI). We sought to identify predictor(s) of limb salvage in CLI patients who received BMCI. Materials and Methods: Nineteen patients with CLI who treated by BMCI were divided into two groups; four patients with above-the-ankle amputation by 12 weeks after BMCI (amputation group) and the remaining 15 patients without (salvage group). We performed several blood-flow examinations before BMCI. Ankle-brachial index (ABI) was measured with the standard method. Transcutaneous oxygen tension (TcPO2) was measured at the dorsum of the foot, in the absence (baseline) and presence (maximum TcPO2) of oxygen inhalation. 99mtechnetium-tetrofosmin (99mTc-TF) perfusion index was determined at the foot and lower leg as the ratio of brain. Results: Maximum TcPO2 (p = 0.031) and 99mTc-TF perfusion index in the foot (p = 0.0068) was significantly higher in the salvage group than in the amputation group. Receiver operating characteristic (ROC) curve analysis identified maximum TcPO2 and 99mTc-TF perfusion index in the foot as having high predictive accuracy for limb salvage. Conclusion: Maximum TcPO2 and 99mTc-TF perfusion index in the foot are promising predictors of limb salvage after BMCI in CLI.


  • Open Access

    Therapeutic Angiogenesis by Autologous Bone Marrow Cell Implantation for Refractory Chronic Peripheral Arterial Disease Using Assessment of Neovascularization by 99mTc-Tetrofosmin (TF) Perfusion Scintigraphy

    by Masaaki Miyamoto, Masahiro Yasutake, Hitoshi Takano, Hiromichi Takagi, Gen Takagi, Hiroshi Mizuno, Shinichiro Kumita, Teruo Takano

    We investigated efficacy and safety of implantation of autologous bone marrow mononuclear cells plus platelets, including endothelial progenitor cells (EPCs), for recovering refractory chronic peripheral arterial disease (PAD) using visual and quantitative analyses by 99mTc-tetrofosmin (TF) perfusion scintigraphy, and also investigated various quantitative assessments objectively. We performed 12 consecutive cases and 19 limbs and hands with severe chronic PAD that were almost Fontaine class IV (11/12 cases, about 92%) in this trial. This treatment was very effective in relieving severe pain of PAD, especially for Buerger's disease. We used a visual analog scale (VAS) for measurement of pain level. The maximum pain level before implantation was 66.5 ± 5.0 mm, and it decreased to 12.1 ± 2.2 mm after implantation (p < 0.001). Rest pain in legs and fingers was resolved in 11 cases (11/12 cases, 92%). All patients could measure pain-free walking time on a treadmill, which improved remarkably (140 ± 53 s before implantation vs. 451 ± 74 s after implantation, p = 0.034). Resting ankle brachial pressure index (ABI) in legs implanted with bone marrow mononuclear cells was also improved (0.65 ± 0.08 before implantation vs. 0.73 ± 0.07 after implantation, p = 0.055). According to 99mTc-TF perfusion scintigraphy, the proximal area (region from knee to ankle) was 1.32 ± 0.10 before implantation versus 1.56 ± 0.11 after implantation (p = 0.007). 99mTc-TF perfusion scintigraphy in the distal area (region from ankle to end of toes, or from wrist to end of fingers) was 0.79 ± 0.06 before implantation versus 0.83 ± 0.06 after implantation (p = 0.29). Ischemic legs and hands that were injected showed increased perfusion blood flow. 99mTc-TF perfusion scintigraphy was effective to estimate visual and quantitative analysis of collateral vessels in neovascularization. We were successful with this new treatment for the most severe, chronic PAD that was not curable by any of the current treatments. Thus, this therapeutic angiogenesis could be a new strategy for saving severe ischemic limbs and hands.


  • Open Access

    [Present status of therapeutic angiogenesis by autologous bone marrow cell implantation for refractory chronic peripheral arterial disease and ischemic heart disease].

    by Masaaki Miyamoto, Masahiro Yasutake, Hitoshi Takano, Gen Takagi, Hiromichi Takagi, Hiroshi Mizuno, Shinichiro Kumita, Masami Ochi, Atsuhiro Sakamoto, Teruo Takano


    • 1 December 2001
      • Vol. 14  (4) , 293-300

    Current progress and perspectives in cell therapy for diabetes mellitus.

    by M Miyamoto

    Recent advances of cell transplantation and tissue engineering are remarkable. And also the diabetic treatment using pancreatic beta cells have performed great advances. Even clinical islet transplantation has been considered a common curative treatment for diabetes mellitus in the place of an experimental treatment. Still more the lack of donor's organ as a worst problem of transplantation will be overcome by using the beta cells produced in vitro culture. Therefore diabetes mellitus will be closed to cure in the near future.